SAB Biotherapeutics holders approve directors, auditor

SAB Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026. A total of 59,349,534 shares were present in person or by proxy out of 77,966,409 shares entitled to vote, representing approximately 76.12% of the outstanding common stock and establishing a quorum.

Shareholders elected four Class II directors for three-year terms: David Zaccardelli, Pharm.D., David Link, MBA, Katie Ellias, and Andrew Moin. Each received over 44 million votes in favor, with broker non-votes of 10,994,436 reported for each nominee.

Stockholders also ratified EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 59,319,363 votes for, 3,373 against, and 26,798 abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares entitled to vote: 77,966,409 shares Shares present: 59,349,534 shares Meeting quorum percentage: 76.12% +5 more

8 metrics

Shares entitled to vote 77,966,409 shares Common stock entitled to vote at 2026 Annual Meeting

Shares present 59,349,534 shares Present in person or by proxy at Annual Meeting

Meeting quorum percentage 76.12% Shares present as a percentage of shares entitled to vote

Votes for Zaccardelli 48,352,114 votes Votes for director David Zaccardelli, Pharm.D.

Votes for Link 44,083,923 votes Votes for director David Link, MBA

Votes for Ellias 48,350,086 votes Votes for director Katie Ellias

Votes for auditor 59,319,363 votes Votes for ratifying EisnerAmper LLP for 2026

Votes against auditor 3,373 votes Votes against ratifying EisnerAmper LLP for 2026

Key Terms

Emerging growth company, broker non-votes, independent registered public accounting firm, quorum, +1 more

5 terms

Emerging growth company regulatory

"Emerging growth company Item 5.07 Submission of Matters to a Vote of Security Holders."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

broker non-votes financial

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"Ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

quorum regulatory

"which represented approximately 76.12% of the outstanding shares entitled to vote at the Annual Meeting and which constituted a quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

Annual Meeting of Stockholders financial

"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SAB Biotherapeutics (SABS) shareholders vote on at the 2026 annual meeting?

Shareholders voted on electing four Class II directors and ratifying EisnerAmper LLP as independent auditor for 2026. These proposals cover board composition and the external firm that reviews the company’s financial statements.

Did SAB Biotherapeutics (SABS) reach a quorum at its 2026 annual meeting?

Yes, a quorum was reached with 59,349,534 shares present out of 77,966,409 entitled to vote, or about 76.12%. This level of participation allowed all agenda items to be validly considered and approved.

Were SAB Biotherapeutics’ 2026 director nominees elected by shareholders?

Yes, all four Class II director nominees were elected. Each nominee received over 44 million votes for, with relatively small withhold votes and 10,994,436 broker non-votes reported for each director position.

Who is the independent auditor ratified by SAB Biotherapeutics (SABS) for 2026?

Shareholders ratified EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was 59,319,363 for, 3,373 against, and 26,798 abstentions.

How strong was support for SAB Biotherapeutics’ auditor ratification proposal?

Support was very high, with 59,319,363 votes for and only 3,373 against, plus 26,798 abstentions. This indicates broad shareholder approval of EisnerAmper LLP as the company’s independent registered public accounting firm.

What percentage of SAB Biotherapeutics (SABS) shares were entitled to vote at the 2026 meeting?

A total of 77,966,409 shares of common stock were entitled to vote at the 2026 Annual Meeting. Of these, 59,349,534 were represented in person or by proxy, satisfying quorum requirements for conducting business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 04:35 PM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 18, 2026

    

SAB BIOTHERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-39871	85-3899721
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

777 W 41st St Suite 401
Miami Beach, Florida		33140
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 305 845-2813

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.0001 par value per share	SABS	The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of Common Stock	SABSW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 18, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The total number of shares of common stock entitled to vote at the Annual Meeting was 77,966,409, and there were 59,349,534 shares present in person or by proxy at the Annual Meeting, which represented approximately 76.12% of the outstanding shares entitled to vote at the Annual Meeting and which constituted a quorum for the transaction of business.

At the Annual Meeting, the shareholders voted to:

(1)

Elect Dr. David Zaccardelli, Pharm.D., Katie Ellias, David Link, MBA, and Andrew Moin, as Class II directors to serve for a term of three years or until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.

(2)

Ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.

The voting results on these proposals were as follows:

Proposal 1: Election of four Class II directors


Director	Votes For	Withheld	Broker Non-Votes
David Zaccardelli, Pharm.D.	48,352,114	2,984	10,994,436
David Link, MBA	44,083,923	4,271,175	10,994,436
Katie Ellias	48,350,086	5,012	10,994,436
Andrew Moin	44,157,704	4,197,394	10,994,436

Proposal 2: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026


Votes For	Votes Against	Abstentions
59,319,363	3,373	26,798

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			SAB Biotherapeutics, Inc.

Date:	June 18, 2026	By:	/s/ Samuel J. Reich
			Samuel J. Reich Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document